Reports & eBooks

Drug Pipeline & Clinical Update - April 2024

May 8, 2024

Capital Rx


  • Three key new drug approvals, including Ojemda™ (torarafenib) for pLGG, the most common brain tumor diagnosed in children
  • Three notable expanded indications, including Fanapt® (iloperidone) for acute treatment of bipolar I disorder
  • One Biosimilar approval and two generic launches
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our April 2024 Monthly Drug Update!

Key New Drug Approvals

Voydeya™ (danicopan) tablet

Approval Date: 04/01/2024 - CLICK HERE for the press release

Indication: Treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) as add-on therapy to ravulizumab or eculizumab

Cost*: $50,261 annually

Key Considerations:

Ojemda™ (torarafenib) tablet; suspension

Approval Date: 04/23/2024 - CLICK HERE for the press release

Indication: Treatment of relapsed or refractory pediatric low-grade glioma (LGG) with BRAF mutation in patients 6 months of age or older

Cost*: $1,211 per tablet

Key Considerations:

Duvyzat™ (givinostat) oral suspension

Approval Date: 04/24/2024 - CLICK HERE for the press release

Indication: Treatment of uncomplicated urinary tract infection (UTI)

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Fanapt® (iloperidone) tablet – expanded to be used for acute treatment of bipolar I disorder

Dovato® (dolutegravir; lamivudine) tablet – expanded to be used for the treatment of HIV-1 infection in patients 12 years of age and older, weight at least 25 kg with no antiviral treatment history or to replace current antiretroviral regimen in those who are virologically suppressed with no history of treatment failure

Alecensa® (alectinib) capsule – expanded to be used as adjuvant treatment following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Biosimilar Approvals

Selarsdi™ (ustekinumab-aekn) subcutaneous injection

Approval Date: 04/16/2024 - CLICK HERE for the press release

Indication: Treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in patients 6 years and older

Additional information:

Generic Launches

Oracea® (doxycycline delayed release 40 mg) capsule

Myrbetriq® (mirabegron ER 24h 25 mg) tablet

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!